Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Болезнь Крона

Список литературы

  1. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn"s disease. Gastroenterology 2002;122:512–30
  2. Reinisch W., Rutgeerts P., Panaccione R., D"Haens G., Thakkar R., Yu A. Identifying appropriate dichotomizing points for SES-CD to predict long-term clinical remission for adalimumab-treated patients with Crohn"s disease. J Crohns Colitis 2010;4:P045
  3. Воробьев Г.И., Халиф И.Л. Неспецифические воспалительные заболевания кишечника. Миклош, 2008.
  4. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–17.
  5. Гастроэнтерология. Национальное руководство / Под ред. В.Т. Ивашкина, Т.Л. Лапиной. ГЭОТАР Медиа, 2008. – 754 c.
  6. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of infl ammatory bowel diseases. Gastroenterology. 2011;140:1785–94.
  7. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(Suppl A): 5–36
  8. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R,et al. Long-term evolution of disease behavior of Crohn"s disease. Inflamm Bowel Dis 2002;8:244–50
  9. Белоусова Е.А. Рекомендации по диагностике и лечению болезни Крона. Фарматека. 2009. № 13. С. 38-44.
  10. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn"s disease activity index. National Cooperative Crohn"s Disease Study. Gastroenterology. 1976 Mar;70(3):439-44.
  11. Григорьева Г.А., Мешалкина Н.Ю. О проблеме системных проявлений воспалительных заболеваний кишечника. Фарматека. 2011. № 15. С. 44-49
  12. Щукина О.Б. Перианальная болезнь Крона: диагностика и медикаментозная терапия. Фарматека. 2008. № 13. С. 22-30
  13. Keighley MR, Allan RN. Current status and influence of operation on perianal Crohn"s disease. Int J Colorectal Dis 1986;1:104–7
  14. Horsthuis K, Bipat S, Bennink RJ, Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: metaanalysis of prospective studies. Radiology 2008;247(1):64–79.
  15. Чашкова Е.Ю., Владимирова А.А., Неустроев В.Г. и др. Воспалительные заболевания толстой кишки - аспекты диагностики. Бюллетень Восточно-Сибирского научного центра СО РАМН. 2011. № 4-2. С. 209-221
  16. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6.
  17. Справочник по колопроктологии под редакцией проф. Ю.А. Шелыгина, проф Л.А. Благодарного. «Литтерра», 2012. C.460-522.
  18. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm.Bowel.Dis. 2004;10:661-665.
  19. D"Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007;22:429-37.
  20. Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004;16:775-8.
  21. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14:1432-42
  22. Nguyen GC, Kaplan GG, Harris ML et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008; 103: 1443-50
  23. Coremans G, Rutgeerts P, Geboes K, et al. The value of ileoscopy with biopsy in the diagnosis of intestinal Crohn"s disease. Gastrointest Endosc 1984;30:167-72.
  24. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013;7:982-1018.
  25. Annunziata M.L. Caviglia R. Papparella L.G. Cicala M. Upper gastrointestinal involvement of Crohn"s disease: a prospective study on the role of upper endoscopy in the diagnostic work-up Dig Dis Sci 57 2012 1618 1623
  26. Gourtsoyiannis NC, Grammatikakis J, Papamastorakis G, et al. Imaging of small intestinal Crohn"s disease: comparison between MR enteroclysis and conventional enteroclysis. Eur Radiol 2006;16:1915-25.
  27. Fraquelli M, Colli A, Casazza G, et al. Role of US in detection of Crohn disease: meta- analysis. Radiology 2005;236:95-101.
  28. Воробьев Г.И., Орлова Л.П., Самсонова Т.В., Капуллер Л.Л., Михайлова Т.Л., Халиф И.Л. Возможности ультразвукового исследования в диагностике болезни крона. Ультразвуковая и функциональная диагностика. 2010. № 1. С. 29-36.
  29. Самсонова Т.В., Орлова Л.П. Ультразвуковая семиотика болезни Крона тонкой кишки. Колопроктология. 2014. №1(47). С. 60-68.
  30. Dionisio P.M. Gurudu S.R. Leighton J.A. Leontiadis G.I. Fleischer D.E. Hara A.K.et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn"s disease: a meta-analysis Am J Gastroenterol 105 2010 1240 1248 [quiz 1249]
  31. Spada C, Riccioni ME, Costamagna G. Patients with known small bowel stricture or with symptoms of small bowel obstruction secondary to Crohn’s disease should not perform video capsule endoscopy without previously tested for small bowel patency. Am J Gastroenterol. 2007; 102:1542-3
  32. Spada C, Shah SK, Riccioni ME et al. Video capsule endoscopy in patients with known or suspected small bowel stricture previously tested with the dissolving patency capsule. J Clin Gastroenterol. 2007; 42:576-82.
  33. Тертычный АС, Андреев АИ, Гебоэс К. Современные подходы к морфологической диагностике воспалительных заболеваний кишечника на материале эндоскопических биопсий. Архив патологии. 2011; Т.73; №1: 40-47
  34. American Gastroenterological Association medical position statement: guidelines for the evaluation and management of chronic diarrhea. Gastroenterology 1999;116(6):1461–3
  35. Корнеева О.И., Ивашкин В.Т. Антибиотико-ассоциированный колит: патоморфология, клиника, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007. Т. 17. № 3. С. 65-71.
  36. Gert Van Assche, Axel Dignass, Julian Panes et al. The second European evidence-based consensus on the diagnosis and management of Crohn"s disease: Current management. Journal of Crohn"s and Colitis (2010) 4, 28–58
  37. Carter MJ, Lobo AJ, Travis SP. IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl 5):V1–V16.
  38. Simms L, Steinhart AH. Budesonide for maintenance of remission in Crohn"s disease. Cochrane Database Syst Rev 2001:CD002913.
  39. Tay GS, Binion DG, Eastwood D, Otterson MF. Multivariate analysis suggests improved perioperative outcome in Crohn"s disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery 2003;34:565–72 discussion 572-3.97
  40. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintaining remission of Crohn"s disease. Cochrane Database Syst Rev 2003(4):CD000301.
  41. Benchimol EI, Seow CH, Steinhart AH, Griffiths AM. Traditional corticosteroids for induction of remission in Crohn"s disease. Cochrane Database Syst Rev 2008;2:CD006792
  42. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006;24:319–30
  43. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn"s disease. Cochrane Database Syst Rev 2009:CD000545.
  44. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn"s disease. Cochrane Database Syst Rev 2000:CD000545.
  45. Herfarth HH, Kappelman MD, Long MD, et al. Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. Inflamm Bowel Dis 2016;22:224-33.
  46. Lémann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn"s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054– 61
  47. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn"s disease. Cochrane Database Syst Rev 2000(2):CD000545
  48. Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn"s disease. Cochrane Database Syst Rev 2008:CD000296.
  49. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn"s disease. Am J Gastroenterol 2000;95:725-9.
  50. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1990 Aug;19(2):126-46.
  51. Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn"s disease: a network meta-analysis. Gastroenterology. 2015 Feb;148(2):344-54.
  52. Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn"s disease. Aliment Pharmacol Ther. 2018 Aug;48(4):394-409.
  53. Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn"s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017 May;45(10):1291- 1302.
  54. Pearson DC, May GR, Fick GR, Sutherland LR. Azathioprine for maintaining remission of Crohn"s disease. Cochrane Database Syst Rev 2000(2):CD000067.
  55. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn"s disease. N Engl J Med 2010;362:1383-95.
  56. Bresci G, Petrucci A, Banti S. 5-aminosalicylic acid in the prevention of relapses of Crohn"s disease in remission: a longterm study. Int J Clin Pharmacol Res 1991;11:200–2
  57. Malchow H, Ewe K, Brandes JW, et al. European co-operative Crohn"s disease study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249–66
  58. Lémann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn"s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006;130:1054– 61
  59. Colombel JF, Rutgeerts P, Reinisch W, et al. SONIC: a randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn"s disease naïve to immunomodulators and biologic therapy. Gut 2008;57 Suppl II:A1
  60. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn"s disease (Cochrane Review). Cochrane Database Syst Rev 2003(1):CD003459
  61. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn"s disease. Gut 1995;37:674-9
  62. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn"s disease. Cochrane Database Syst Rev 2009;1:CD006893.
  63. D"Haens G, Baert F, van Assche G, et al. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn"s disease: an open randomised trial. Lancet 2008;371:660–7
  64. Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Abadir A, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:661–73.
  65. Ohkusa T, Kato K, Terao S, Chiba T, Mabe K, Murakami K, et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 2010;105:1820–9.
  66. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015;9:211-22.
  67. Scand J Gastroenterol Suppl. 1998;225:92-9. Azathioprine: state of the art in inflammatory bowel disease. Sandborn WJ.
  68. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn"s disease. Gastroenterology 2004;126:402–13.
  69. Colombel JF, Rutgeerts P, Reinisch W, et al. SONIC: a randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn"s disease naïve to immunomodulators and biologic therapy. Gut 2008;57 Suppl II:A1.
  70. Strong SA, Koltun WA, Hyman NH, Buie WD, Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for the surgical management of Crohn’s disease. Dis Colon Rectum. 2007;50:1735–46.
  71. Billioud V, Ford AC, Tedesco ED, Colombel JF, Roblin X, Peyrin-Biroulet L. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta- analysis. Journal of Crohn"s & colitis. 2013;7(11):853-67.
  72. Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH. Anti-tumor necrosis factor and postoperative complications in Crohn"s disease: systematic review and meta-analysis. Inflammatory Bowel Diseases. 2012;18(12):2404-13.
  73. Selvaggi F, Pellino G, Canonico S, Sciaudone G. Effect of preoperative biologic drugs on complications and function after restorative proctocolectomy with primary ileal pouch formation: systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(1):79-92.
  74. Yang ZP, Hong L, Wu Q, Wu KC, Fan DM. Preoperative infliximab use and postoperative complications in Crohn"s disease: a systematic review and meta-analysis. International Journal Of Surgery. 2014;12(3):224-30.
  75. Успенская Ю.Б., Белогубова С.Ю. Диагностические возможности применения фекального кальпротектина у пациентов с воспалительными заболеваниями кишечника в период беременности (обзор литературы и клинические наблюдения). Колопроктология. 2018. №2(64). С.95-101.
  76. Хачатурова Э.А., Ерошкина Т.Д., Блинова О.В., и др. Коррекция нарушений метаболизма в раннем послеоперационном периоде при тяжелых формах неспецифического язвенного колита и болезни Крона. // «Российский журнал гастроэнтерологии, гепатологии, колопроктологии», 2003, т. 8, № 4, с.63-68.
  77. Korzenik JR. Massive lower gastrointestinal hemorrhage in Crohn’s disease. Curr Treat Options Gastroenterol. 2000;3:211–6.
  78. Bundred NJ, Dixon JM, Lumsden AB, Gilmour HM, Davies GC. Free perforation in Crohn’s colitis. A ten-year review. Dis Colon Rectum. 1985;28:35–7.
  79. Werbin N, Haddad R, Greenberg R, Karin E, Skornick Y. Free perforation in Crohn’s disease. Isr Med Assoc J. 2003;5:175–7.
  80. Papi C, Festa V, Fagnani C, Stazi A, Antonelli G, Moretti A, et al. Evolution of clinical behaviour in Crohn’s disease: predictive factors of penetrating complications. Dig Liver Dis. 2005;37:247–53.
  81. Poggioli G, Stocchi L, Laureti S, Selleri S, Marra C, Magalotti C, et al. Conservative surgical management of terminal ileitis: side-to-side enterocolic anastomosis. Dis Colon Rectum. 1997;40:234–7.
  82. Melton GB, Fazio VW, Kiran RP, He J, Lavery IC, Shen B, et al. Long-term outcomes with ileal pouch-anal anastomosis and Crohn’s disease: pouch retention and implications of delayed diagnosis. Ann Surg. 2008;248:608–16.
  83. Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7(7):556-85.
  84. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn"s disease: Current management. J Crohns Colitis. 2010;4(1):28-62.
  85. Варданян А.В., Кашников В.Н., Болихов К.В., Халиф И.Л. Лапароскопическая илеостомия при болезни Крона. Колопроктология, 2011, №3 (37), с. 20-23.
  86. Воробьев Г.И., Болихов К.В., Варданян А.В. Место лапароскопической илеостомии в лечении болезни Крона толстой кишки (обзор литературы). Колопроктология, 2009, №3 (29), с. 52-58.
  87. Sagar PM, Dozois RR, Wolff BG. Long-term results of ileal pouch-anal anastomosis in patients with Crohn’s disease. Dis Colon Rectum. 1996;39:893–8.
  88. Simillis C, Purkayastha S, Yamamoto T, Strong SA, Darzi AW, Tekkis PP. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn"s disease. Dis Colon Rectum 2007;50(10):1674–87
  89. Stocchi L, Milsom JW, Fazio VW. Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn’s disease: follow-up of a prospective randomized trial. Surgery. 2008;144:622– 7.
  90. Tekkis PP, Purkayastha S, Lanitis S, Athanasiou T, Heriot AG, Orchard TR, et al. A comparison of segmental vs. subtotal/total colectomy for colonic Crohn’s disease: a meta-analysis. Colorectal Dis. 2006;8:82–90.
  91. Mege D., Panis Y. Laparoscopic surgery for inflammatory bowel disease. Колопроктология. 2018. №2(64). С. 14-24.
  92. Byrne CM, Solomon MJ, Young JM, Selby W, Harrison JD. Patient preferences between surgical and medical treatment in Crohn’s disease. Dis Colon Rectum. 2007;50:586–97.
  93. Щукина О.Б., Собко В.Ю., Горбачева Д.Ш., Григорян В.В., Насыхова Ю.А. Васильев С.В. Прогнозирование хирургического лечения болезни Крона. Колопроктология. 2015. №4(54). С. 33-40.
  94. Tichansky D, Cagir B, Yoo E, Marcus SM, Fry RD. Strictureplasty for Crohn’s disease: meta- analysis. Dis Colon Rectum. 2000;43:911–9.
  95. Reese GE, Purkayastha S, Tilney HS, von Roon A, Yamamoto T, Tekkis PP. Strictureplasty vs. resection in small bowel Crohn’s disease: an evaluation of short-term outcomes and recurrence. Colorectal Dis. 2007;9:686–94.
  96. Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and meta-analysis. Dis Colon Rectum. 2007;50:1968–86.
  97. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006;55 Suppl 1:i36–58.
  98. Dietz DW, Laureti S, Strong SA, Hull TL, Church J, Remzi FH, et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn’s disease. J Am Coll Surg. 2001;192:330–7.
  99. Шелыгин Ю.А., Халиф И.Л, Кашников В.Н., Болихов К.В., Варданян А.В. Илеостомия в лечении болезни Крона толстой кишки с перианальными поражениями. «Колопроктология», 2011, №3 (37), с. 133.
  100. Шапина М.В., Халиф И.Л., Нанаева Б.А. Применение цертолизумаба пэгола при болезни Крона. Обзор литературы. Колопроктология. 2016.№3(57). С. 102-108.
  101. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn"s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328–32
  102. Gecse KB, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn"s disease. Gut. 2014;63(9):1381-92.
  103. van Dongen LM, Lubbers EJC. Perianal fistulas in patients with Crohn’s disease. Arch Surg. 1986;121:1187–90.
  104. Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal Crohn’s disease. World J Surg. 2000;24:1258–62.
  105. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn"s disease. Gastroenterology 1990;99:956–63
  106. Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504–17
  107. Полетова А.В., Шапина М.В., Халиф И.Л., Варданян А.В. Эффективность послеоперационной противорецидивной терапии Адалимумабом и азатиоприном при болезни Крона. Колопроктолгия. 2018. №2(64). С. 73-77.
  108. Peyrin-Biroulet, L., et al., Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn"s disease: a meta-analysis. Am J Gastroenterol, 2009. 104(8): p. 2089-96.
  109. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136:441–50.
  110. Terdiman, J.P., Prevention of postoperative recurrence in Crohn"s disease. Clin Gastroenterol Hepatol, 2008. 6(6): p. 616-20
  111. Papamichael, K., et al., Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn"s disease: a prospective, two-year, single center, pilot study. J Crohns Colitis, 2012. 6(9): p. 924-31
  112. Халиф И.Л., Варданян А.В., Шапина М.В., Полетова А.В. Противорецидивная терапия болезни Крона в послеоперационном периоде (обзор литературы). Колопроктология. 2017. №3(61). С. 63-70.
  113. Loly C, Belaiche J, Louis E. Predictors of severe Crohn"s disease. Scand J Gastroenterol 2008;43:948–54.
  114. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211-22.
  115. Aguado J. M., Anttila V. J., Galperine T., GoldenbergS. D. et al. Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line. J. Hosp. Infect. – 2015. – № 2(50). – Р. 117-125.
  116. Metan G., Tьre Z., Kaynar L. Tigecycline for the treatment of Clostridium difficile infection refractory to metronidazole in haematopoietic stem cell transplant recipients. Journal of Chemotherapy. – 2015. – № 6 (27). – Р. 354–357.
  117. Tschudin-Sutter S. Braissant O., Erb S., et al. Growth Patterns of Clostridium difficile – Correlations with Strains, Binary Toxin and Disease Severity: A Prospective Cohort Study. PLoS One. – 2016. – № 9(11). – Р. e0161711.
  118. Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., Алешин Д.В., Калашникова А.И., Белоусова С.В., Егорова Д.В. Современные возможности улучшения функционального состояния запирательного аппарата у пациентов с наличием превентивных кишечных стом. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2015. – 5. – С.77-83
  119. Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., Джанаев Ю.А., Алешин Д.В., Егорова Д.В. Роль аноректальной манометрии, БОС-терапии и тибиальной нейромодуляции в диагностике и консервативном лечении анальной инконтиненции у пожилых. Клиническая геронтология. 2015. - 5-6. – С.16-20
  120. Froslie KF, Jahnsen J, Moum BA, VatnMH. Group I.Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–22
  121. Rahier, J.F., et al., European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis, 2009. 3(2): p. 47-91
  122. Gert Van Assche, Axel Dignass, Julian Panes et al. The second European evidence-based consensus on the diagnosis and management of Crohn"s disease: Definitions and diagnosis. Journal of Crohn"s and Colitis (2010) 4, 7–27
  123. OCEBM Levels of Evidence Working Group. "The Oxford 2011 Levels of Evidence". Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/ocebm-levels-of-evidence
  124. Nolan DJ.Radiology of inflammatory bowel disease.Br J Hosp Med. 1986 Aug;36(2):128-32
  125. Long B, Robertson J, Koyfman A.Emergency Medicine Evaluation and Management of Small Bowel Obstruction: Evidence-Based Recommendations.J Emerg Med. 2019 Feb;56(2):166-176. doi: 10.1016/j.jemermed.2018.10.024. Epub 2018 Dec 6.
  126. Cameron DJ. Upper and lower gastrointestinal endoscopy in children and adolescents with Crohn"s disease: a prospective study.J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):355-8.
  127. Thakkar K, Lucia CJ, Ferry GD, McDuffie A, et al.Repeat endoscopy affects patient management in pediatric inflammatory bowel disease.Am J Gastroenterol. 2009 Mar;104(3):722-7. doi: 10.1038/ajg.2008.111. Epub 2009 Feb 10.
  128. Church PC, Kuint RC, Ledder O, Navas-López VM, et al. Magnetic Resonance Enterography Cannot Replace Upper Endoscopy in Pediatric Crohn Disease: An Imagekids Sub-study.J Pediatr Gastroenterol Nutr. 2018 Jul;67(1):53-58. doi: 10.1097/MPG.0000000000001869.
  129. Bettenworth D, Bokemeyer A, Baker M, Mao R, et al.Assessment of Crohn"s disease- associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review.
  130. Chidi VN, Schwartz DA.Imaging of perianal fistulizing Crohn"s disease.Expert Rev Gastroenterol Hepatol. 2015 Jun;9(6):797-806. doi: 10.1586/17474124.2015.1031110. Epub 2015 Mar 30.
  131. Sheedy SP, Bruining DH, Dozois EJ, Faubion WA, Fletcher JG.MR Imaging of Perianal Crohn Disease.Radiology. 2017 Mar;282(3):628-645. doi: 10.1148/radiol.2016151491.
  132. Schulz C, Mönkemüller K, Salheiser M, et al. Double-balloon enteroscopy in the diagnosis of suspected isolated Crohn"s disease of the small bowel.Dig Endosc. 2014 Mar;26(2):236-42. doi: 10.1111/den.12142. Epub 2013 Jul 16.
  133. Coward S, Kuenzig ME, Hazlewood G, Clement F, et al.Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn"s Disease: A Bayesian Network Meta-analysis.Inflamm Bowel Dis. 2017 Mar;23(3):461-472. doi: 10.1097/MIB.0000000000001023.
  134. Rezaie A, Kuenzig ME, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn"s disease.Cochrane Database Syst Rev. 2015 Jun 3;(6):CD000296. doi: 10.1002/14651858.CD000296.pub4.
  135. Rahier JF, Magro F, Abreu C, Armuzzi A, et al.Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014 Jun;8(6):443-68. doi: 10.1016/j.crohns.2013.12.013. Epub 2014 Mar 6.
  136. de Ridder, Lissy; Assa, Amit; Bronsky, Jiriet al. Use of Biosimilars in Pediatric Inflammatory Bowel Disease. An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN ; J Pediatr Gastroenterol Nutr 2018;68:144–53
  137. Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6- mercaptopurine for maintenance of remission in Crohn"s disease. Cochrane Database Syst Rev. 2015 Oct 30;(10):CD000067.
  138. Chande N, Townsend CM, Parker CE, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in Crohn"s disease. Cochrane Database Syst Rev. 2016 Oct 26;10:CD000545.
  139. Ledder O, Turner D. Antibiotics in IBD: Still a Role in the Biological Era? Inflamm Bowel Dis. 2018 Jul 12;24(8):1676-1688.
  140. Steinhart AH, Panaccione R, Targownik L, et al. Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn"s Disease: The Toronto Consensus. Inflamm Bowel Dis. 2019 Jan 1;25(1):1-13. doi: 10.1093/ibd/izy247.
  141. Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn"s disease: a randomized controlled trial. Am J Gastroenterol. 2013 Nov;108(11):1731-42. doi: 10.1038/ajg.2013.287.
  142. Yamada A, Komaki Y, Patel N, et al. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn"s Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):502-509.
  143. Brand EC, Elias SG, Minderhoud IM, et al. Systematic review and external validation of prediction models based on symptoms and biomarkers for identifying endoscopic activity in Crohn"s disease. Clin Gastroenterol Hepatol. 2019 Dec 24. pii: S1542-3565(19)31493-4.
  144. Lu TX, Cohen RD. Maneuvering Clinical Pathways for Crohn"s Disease. Curr Gastroenterol Rep. 2019 Apr 23;21(5):20.
  145. Bhattacharya A1, Shen B1, Regueiro M2. Endoscopy in Postoperative Patients with Crohn"s Disease or Ulcerative Colitis. Does It Translate to Better Outcomes? Gastrointest Endosc Clin N Am. 2019 Jul;29(3):487-514. doi: 10.1016/j.giec.2019.02.013.
  146. Chu KF1, Moran CJ2, Wu K1, et al. Performance of Surveillance MR Enterography (MRE) in Asymptomatic Children and Adolescents With Crohn"s Disease. J Magn Reson Imaging. 2019 Dec;50(6):1955-1963. doi: 10.1002/jmri.26811.
  147. Deepak P1, Axelrad JE2, Ananthakrishnan AN3. The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. Gastrointest Endosc Clin N Am. 2019 Jul;29(3):447-470. doi: 10.1016/j.giec.2019.02.006.
  148. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005. 172(9): 1169-227.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*